This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Hextend

Pfizer Inc.

Drug Names(s): Hetastarch 670/0.75, HES 670/0.75, hydroxyethyl starch 670/0.75

Description: HEXTEND (6% Hetastarch in Lactated Electrolyte Injection) is an artificial colloidal solution that resembles the composition of the principal ionic constituents of normal plasma. It is classified as a plasma volume expander, and is intended to support oncotic pressure as well as provide electrolytes.

Hextend has hydroxyethyl groups attached to the glucose units, with a molar substitution of about 0.75 (75 hydroxyethyl groups for every 100 glucose units). The average molecular weight is about 670,000 with a range of 450,000 to 800,000, and with at least 80% of the polymer units within 20,000 to 2,500,000.

Deal Structure: BioTime and Summit
In December 2004, BioTime entered into an agreement with Summit Pharmaceuticals International to co-develop Hextend for the Japanese market.

Summit and Maruishi
In July 2005, Summit sublicensed the rights to Hextend in Japan to Maruishi Pharmaceutical. In consideration for the license, Maruishi agreed to pay Summit a series of milestone payments.

Hextend is distributed in the U.S. by Hospira. Under the license agreement, Hospira will report sales of Hextend and pay BioTime royalties and license fees due on account of such sales after the end of each calendar quarter.

Pfizer and Hospira
In February 2015, Pfizer and Hospira announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be...See full deal structure in Biomedtracker

Partners: BioTime, Inc. Summit Pharmaceuticals International Maruishi Pharmaceutical Co., Ltd.


Hextend News

Pink Sheet BioTime Hextend

Pink Sheet FDA 1999 stats


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug